clinical trial · NCT07399730
Ravulizumab Outcomes in Polish Patients With aHUS
Atypical Hemolytic Uremic SyndromeRavulizumab
brief summary
This multicenter, observational cohort study uses retrospective collection of past medical history and prospective follow-up to capture longitudinal data on the management and clinical outcomes of patients with atypical hemolytic uremic syndrome (aHUS) treated with ravulizumab as part of routine clinical practice under Poland's National Drug Program (NDP).
started
Jun 24, 2026
primary completion
Sep 30, 2029
completion
Sep 30, 2029
last updated
Sep 15, 2026
official title
A Non-interventional Study Evaluating Ravulizumab Treatment Outcomes in Polish Patients With Atypical Hemolytic Uremic Syndrome
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol